J.B. Chemicals & Pharmaceuticals (JBCPL) has agreed to acquire certain probiotic brands and infertility and hormone products for the Indian market from Sanzyme in a deal worth around INR 628 crores.

The probiotics brands involved in the deal are Sporlac and specialized products such as Lobun, which is a probiotic for delaying progression of chronic kidney disease, and Oxalo, an alternate risk-free therapy to decalcify kidney stones.

The brands are said to have a pan-India footprint and wide distribution reach of around 300,000 chemists and nearly 100,000 prescribers.

The acquisition also involves a complete variety of infertility and hormone products.

According to IQVIA MAT Dec 21 data, the combined revenue of the brands was INR 160 crores.

Nikhil Chopra — J.B. Chemicals & Pharmaceuticals CEO and Whole-time Director said: “We are glad to announce our first acquisition which expands our presence into new Therapeutic areas and also increases the addressable opportunity in the India Pharma market. This is in line with our stated objective of building big brands through category leaders. Sanzyme has been a pioneer in the probiotics segment and we wish to build further on this legacy.

“This acquisition also reinforces our strategic intent to evaluate opportunities to supplement our growth ambition in India. Overall, our objective is to deploy capital judiciously to enhance value for all stakeholders.”

The deal, which is subject to customary closing formalities, is expected to close in the next two weeks.

  India, J.B. Chemicals & Pharmaceuticals, JBCPL, Lobun, Nikhil Chopra, Oxalo, Pharma acquisition news, probiotics, reproductive health, Sanzyme, Sporlac